Filed under: Bad news, Products and services, Pfizer (PFE), Options, Technical AnalysisPfizer Inc. (NYSE: PFE) stock is falling this morning as the FDA said late yesterday afternoon that it will investigate reports of mood disorders, violent behavior, and suicidal reports among patients taking Chantix, an anti-smoking drug made by PFE. The FDA is still collecting information on the drug, but advised doctors to exercise caution in prescribing the drug. Chantix was approved for use by the FDA last year, and has generated sales in excess of $100 million for PFE. PFE responded Tuesday that there is no scientific evidence establishing a causal relationship between Chantix and these symptoms. If you think this stock won't be rising too far in the coming months, then it could be a good time to lo
Related Headlines
- Top cash-rich turnarounds: Microsoft, Motorola, Corning & Pfizerposted 836 weeks ago on BloggingStocks
- Leaving the Microsoft world for Appleposted 836 weeks ago on BloggingStocks
- Closing Bell: Last minute mini-rally avoids larger disaster; KO, PFE, S, JASOposted 772 weeks ago on BloggingStocks
- The Wal-Mart Weekly: Next year, try a little innovation for Black Friday marketingposted 836 weeks ago on BloggingStocks
- Israel launches anti-hijack systemposted 836 weeks ago on BloggingStocks
- Wall Street turkeys get pardon as Fed lets consumers pay for rampant inflationposted 836 weeks ago on BloggingStocks
- McDonald's: Do you want pot with that?posted 836 weeks ago on BloggingStocks
- Hottest Products of 2007: 'Halo 3' comes out firingposted 836 weeks ago on BloggingStocks
- Microsoft (MSFT) Zune sold out?posted 836 weeks ago on BloggingStocks